Minara Shamkhalovna Shamkhalova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Minara Shamkhalovna Shamkhalova has a total of 407 co-authors. Here are the top co-authors by number of shared publications:
- Marina Vladimirovna Shestakova
Endocrinology Research Centre, 117292 Moscow, Russia
71 shared publications - Anastasia Sergeevna Severina
Endocrinology Research Centre
21 shared publications - Olga Yuryevna Sukhareva
Endocrinology Research Centre
19 shared publications - Ol'Ga Konstantinovna Vikulova
Endocrinology Research Centre
18 shared publications - Gagik Radikovich Galstyan
Endocrinology Research Centre
17 shared publications - Ivan Ivanovich Dedov
Endocrinology Research Centre
17 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 29 (4) , 374-385
Post-transplant diabetes mellitus: mechanisms of development, risk factors, diagnosis, treatment
The progressive increase in transplant activity is expected to increase the incidence of post-transplant complications, particularly post-transplant diabetes mellitus (PTDM). This review analyzes the epidemiology, risk factors, and key mechanisms for the development of this complication, such as immunosuppressive therapy-induced insulin resistance and impaired insulin secretion due to calcineurin inhibitor toxicity. Non-modifiable and modifiable risk factors are considered. Particular attention is paid to the evolution of terminology and diagnostic criteria PTDM, their specificity in the post-transplant period, and the role of continuous glycemic monitoring for active screening of recipients. A comparative analysis of current therapeutic approaches is presented, covering modifications of immunosuppressive regimens, non-pharmacological interventions, and the use of incretin mimetics, sodium-glucose cotransporter-2 inhibitors, and other hypoglycemic agents in this population. Further prospects in post-transplant patient management tactics are discussed — replacing drugs with less diabetogenic ones, improving immunosuppression protocols, a personalized approach, and early stratification of the risk of developing PTDM. The clinical significance of PTDM as a factor associated with a worse cardiovascular prognosis and reduced graft and recipient survival is emphasized. The need for interdisciplinary collaboration between transplant surgeons, endocrinologists and internists at all stages of patient management is substantiated — from pre-transplant assessment of metabolic status to long-term postoperative follow-up.
- 1 October 2026
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 29 (4) , 374-385
Open AccessPost-transplant diabetes mellitus: mechanisms of development, risk factors, diagnosis, treatment
The progressive increase in transplant activity is expected to increase the incidence of post-transplant complications, particularly post-transplant diabetes mellitus (PTDM). This review analyzes the epidemiology, risk factors, and key mechanisms for the development of this complication, such as immunosuppressive therapy-induced insulin resistance and impaired insulin secretion due to calcineurin inhibitor toxicity. Non-modifiable and modifiable risk factors are considered. Particular attention is paid to the evolution of terminology and diagnostic criteria PTDM, their specificity in the post-transplant period, and the role of continuous glycemic monitoring for active screening of recipients. A comparative analysis of current therapeutic approaches is presented, covering modifications of immunosuppressive regimens, non-pharmacological interventions, and the use of incretin mimetics, sodium-glucose cotransporter-2 inhibitors, and other hypoglycemic agents in this population. Further prospects in post-transplant patient management tactics are discussed — replacing drugs with less diabetogenic ones, improving immunosuppression protocols, a personalized approach, and early stratification of the risk of developing PTDM. The clinical significance of PTDM as a factor associated with a worse cardiovascular prognosis and reduced graft and recipient survival is emphasized. The need for interdisciplinary collaboration between transplant surgeons, endocrinologists and internists at all stages of patient management is substantiated — from pre-transplant assessment of metabolic status to long-term postoperative follow-up.
- Open Access
- 1 October 2026
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 29 (4) , 386-392
Periodontal Diseases in Patients with Type 1 Diabetes Mellitus: Pathogenetic and Clinical Aspects
INTRODUCTION: Periodontal diseases in patients with type 1 diabetes mellitus (T1DM) represent a multifactorial clinicopathogenetic problem, driven by disturbances in carbohydrate metabolism, immune response, and microcirculation. Despite advances in modern medicine, timely diagnosis and optimization of therapy for periodontal diseases in T1DM remain of high clinical and scientific significance. OBJECTIVE: To systematize current data on pathogenetic and clinical aspects underlying the bidirectional relationship between T1DM and periodontal diseases. MATERIALS AND METHODS: We analyzed scientific publications from the past 20 years in PubMed, Scopus, and Google Scholar using key terms: “type 1 diabetes mellitus”, “periodontal diseases in type 1 diabetes”, “periodontitis”, and “bidirectional relationship”. KEY FINDINGS: Current evidence confirms the presence of a bidirectional relationship between T1DM and periodontal diseases. Chronic hyperglycemia contributes to the development and progression of periodontitis through alterations in the oral microbiome, activation of the AGEs–RAGE signaling pathway, microvascular dysfunction, neutrophil impairment, and defective reparative processes. Conversely, chronic periodontal inflammation exacerbates systemic inflammation and is associated with worsened glycemic control. These findings highlight the multifactorial pathogenesis of periodontal diseases in T1DM and underscore the need for an interdisciplinary approach and early diagnosis. CONCLUSION: Improvement of early diagnostic methods and implementation of interdisciplinary, personalized management strategies for patients with T1DM and periodontal diseases may enhance clinical outcomes. A promising direction is the development and validation of integrated clinical–laboratory algorithms for risk assessment and prognosis of dental complications in T1DM.
- 1 October 2026
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 29 (4) , 386-392
Open AccessPeriodontal Diseases in Patients with Type 1 Diabetes Mellitus: Pathogenetic and Clinical Aspects
INTRODUCTION: Periodontal diseases in patients with type 1 diabetes mellitus (T1DM) represent a multifactorial clinicopathogenetic problem, driven by disturbances in carbohydrate metabolism, immune response, and microcirculation. Despite advances in modern medicine, timely diagnosis and optimization of therapy for periodontal diseases in T1DM remain of high clinical and scientific significance. OBJECTIVE: To systematize current data on pathogenetic and clinical aspects underlying the bidirectional relationship between T1DM and periodontal diseases. MATERIALS AND METHODS: We analyzed scientific publications from the past 20 years in PubMed, Scopus, and Google Scholar using key terms: “type 1 diabetes mellitus”, “periodontal diseases in type 1 diabetes”, “periodontitis”, and “bidirectional relationship”. KEY FINDINGS: Current evidence confirms the presence of a bidirectional relationship between T1DM and periodontal diseases. Chronic hyperglycemia contributes to the development and progression of periodontitis through alterations in the oral microbiome, activation of the AGEs–RAGE signaling pathway, microvascular dysfunction, neutrophil impairment, and defective reparative processes. Conversely, chronic periodontal inflammation exacerbates systemic inflammation and is associated with worsened glycemic control. These findings highlight the multifactorial pathogenesis of periodontal diseases in T1DM and underscore the need for an interdisciplinary approach and early diagnosis. CONCLUSION: Improvement of early diagnostic methods and implementation of interdisciplinary, personalized management strategies for patients with T1DM and periodontal diseases may enhance clinical outcomes. A promising direction is the development and validation of integrated clinical–laboratory algorithms for risk assessment and prognosis of dental complications in T1DM.
- Open Access
- 1 October 2026
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 29 (4) , 419-426
A personalized approach to the treatment of neonatal diabetes mellitus caused by a KCNJ11 mutation: clinical observations
Neonatal diabetes mellitus (NDM), or diabetes of the newborn, belongs to the group of monogenic forms of the disease and is characterized by marked genetic polymorphism. It is a rare genetically determined disorder with early onset (typically within the first 6 months of life), manifesting as persistent hyperglycemia associated with impaired insulin secretion. To date, more than 30 genes have been identified as being involved in the development of NDM. Among these, mutations in the KCNJ11 , ABCC8 , and INS genes account for nearly 70% of cases of the permanent form of the disease. Of particular clinical importance are mutations in genes encoding potassium channel function ( KCNJ11 , ABCC8 ), as treatment with sulfonylureas, which help normalize channel activity, can restore insulin secretion and enable patients to transition from insulin therapy to oral glucose-lowering agents. In most patients, such a transition is possible at any age; however, early initiation of sulfonylurea therapy (during the first months of life) is of critical importance, as it may prevent central nervous system damage, which is frequently observed in patients with these mutations. The identification of genetic mutations has become a key tool for clinicians, enabling precise diagnosis and the selection of the most effective treatment strategies. Timely diagnosis facilitates the initiation of optimal glucose-lowering therapy aimed at achieving target glycemic levels and reducing the risk of complications, particularly those affecting the central nervous system, as well as specific complications of diabetes mellitus. This article presents two clinical cases of female patients aged 30 and 33 years with NDM, in whom the KCNJ11 p.R201C mutation was identified in adulthood, followed by successful transition from insulin therapy to pathogenetically targeted glucose-lowering treatment.
- 1 October 2026
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 29 (4) , 419-426
Open AccessA personalized approach to the treatment of neonatal diabetes mellitus caused by a KCNJ11 mutation: clinical observations
Neonatal diabetes mellitus (NDM), or diabetes of the newborn, belongs to the group of monogenic forms of the disease and is characterized by marked genetic polymorphism. It is a rare genetically determined disorder with early onset (typically within the first 6 months of life), manifesting as persistent hyperglycemia associated with impaired insulin secretion. To date, more than 30 genes have been identified as being involved in the development of NDM. Among these, mutations in the KCNJ11 , ABCC8 , and INS genes account for nearly 70% of cases of the permanent form of the disease. Of particular clinical importance are mutations in genes encoding potassium channel function ( KCNJ11 , ABCC8 ), as treatment with sulfonylureas, which help normalize channel activity, can restore insulin secretion and enable patients to transition from insulin therapy to oral glucose-lowering agents. In most patients, such a transition is possible at any age; however, early initiation of sulfonylurea therapy (during the first months of life) is of critical importance, as it may prevent central nervous system damage, which is frequently observed in patients with these mutations. The identification of genetic mutations has become a key tool for clinicians, enabling precise diagnosis and the selection of the most effective treatment strategies. Timely diagnosis facilitates the initiation of optimal glucose-lowering therapy aimed at achieving target glycemic levels and reducing the risk of complications, particularly those affecting the central nervous system, as well as specific complications of diabetes mellitus. This article presents two clinical cases of female patients aged 30 and 33 years with NDM, in whom the KCNJ11 p.R201C mutation was identified in adulthood, followed by successful transition from insulin therapy to pathogenetically targeted glucose-lowering treatment.
- Open Access
- 8 September 2026
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 72 (4) , 10-17
Resolution of the Joint Meeting of the Expert Council "Hypoparathyroidism in the Era of Complex Problems and Breakthrough Technologies"
On March 25, 2026, a meeting of the Expert Council entitled "Hypoparathyroidism in the Era of Complex Challenges and Breakthrough Technologies" was held in Moscow at the Endocrinology Research Centre. The meeting focused on the epidemiology of chronic hypoparathyroidism (hypoPT) in Russia, the specifics of patient management with this pathology in other countries, and the similarities and differences between international and Russian clinical guidelines. The meeting discussed advances in improving diagnostics and personalized treatment for patients with hypoPT in Russia, as well as the need to implement best practices in practical healthcare as part of the 2027 clinical guidelines revision. The importance of including chronic hypoPT in the official list of rare (orphan) diseases was highlighted, as was the need to continue studying the characteristics of the disease and its complications, diagnosis, monitoring, and prevention of hypoPT, including in the long term. The meeting also highlighted the relevance of an interdisciplinary professional alliance to achieve optimal treatment outcomes and improve the quality of life of patients with chronic hypoPT. The experts highlighted the need to implement innovative, effective treatment methods, including hormone replacement therapy for hypoPT. The Council discussed the efficacy and safety of the new therapeutic technology, TransCon parathyroid hormone. Invited expert Dilek Gogas Yavuz, MD, Professor at the Marmara University School of Medicine, Department of Endocrinology and Metabolism, Department of Internal Medicine (Istanbul, Turkey), shared her experience with the drug and the results of international clinical trials. This resolution is a summary of the issues discussed in the Council members’ presentations and during the professional discussions.
- 8 September 2026
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 72 (4) , 10-17
Open AccessResolution of the Joint Meeting of the Expert Council "Hypoparathyroidism in the Era of Complex Problems and Breakthrough Technologies"
On March 25, 2026, a meeting of the Expert Council entitled "Hypoparathyroidism in the Era of Complex Challenges and Breakthrough Technologies" was held in Moscow at the Endocrinology Research Centre. The meeting focused on the epidemiology of chronic hypoparathyroidism (hypoPT) in Russia, the specifics of patient management with this pathology in other countries, and the similarities and differences between international and Russian clinical guidelines. The meeting discussed advances in improving diagnostics and personalized treatment for patients with hypoPT in Russia, as well as the need to implement best practices in practical healthcare as part of the 2027 clinical guidelines revision. The importance of including chronic hypoPT in the official list of rare (orphan) diseases was highlighted, as was the need to continue studying the characteristics of the disease and its complications, diagnosis, monitoring, and prevention of hypoPT, including in the long term. The meeting also highlighted the relevance of an interdisciplinary professional alliance to achieve optimal treatment outcomes and improve the quality of life of patients with chronic hypoPT. The experts highlighted the need to implement innovative, effective treatment methods, including hormone replacement therapy for hypoPT. The Council discussed the efficacy and safety of the new therapeutic technology, TransCon parathyroid hormone. Invited expert Dilek Gogas Yavuz, MD, Professor at the Marmara University School of Medicine, Department of Endocrinology and Metabolism, Department of Internal Medicine (Istanbul, Turkey), shared her experience with the drug and the results of international clinical trials. This resolution is a summary of the issues discussed in the Council members’ presentations and during the professional discussions.
- Open Access
- 26 July 2026
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 29 (3) , 245-255
Sarcopenia in postmenopausal patients with type 1 diabetes mellitus: characteristics of functional, laboratory, and instrumental indicators
BACKGROUND . Patients with type 1 diabetes mellitus (T1DM) are prone to earlier development of sarcopenia due to insulin deficiency, hyperglycemia, oxidative stress, and mitochondrial dysfunction. A pressing challenge in the management of these patients is the search for standardized diagnostic tools for the timely detection and monitoring of sarcopenia. OBJECTIVE . Comparative assessment of laboratory serum myokine levels in relation to muscle mass, strength, and function in postmenopausal women with type 1 diabetes and controls without diabetes. MATERIALS AND METHODS . A single-center, cross-sectional comparative study was conducted in women with type 1 diabetes (n=40) and a control group (n=40) aged 50–75 years. The SARC-F questionnaire, laboratory parameters (myostatin, follistatin, cystatin C, lipocalin 2, IGF-1), muscle mass (iDXA densitometry), strength (wrist dynamometry), and function (short-form exercise battery) were assessed. Statistical processing was performed in Statistica 14.0.0.15, IBM SPSS Statistics 23 using the Mann-Whitney, Fisher, and Spearman correlation tests. RESULTS . The age of the patients was 60 [56;64] years in the T1DM group and 64 [60;66] years in the control group (p=0.029). Glycated hemoglobin (HbA 1c ) in the T1DM group was 8.0% [7.6;9.3] with a diabetes duration of 26 [13;42] years. The myostatin level was significantly higher in T1DM 52.73 [46.45;58.26] mg/ml versus 21.46 [19.07;24.74] in the control (p < 0.001) and positively correlated with HbA 1c (r=0.544, p < 0.001), but not with muscle strength and mass. HbA1c negatively correlated with the time it took to get up from a chair 5 times. No differences were found in the levels of follistatin, lipocalin 2, cystatin C. Wrist dynamometry strength and walking speed were lower in the T1DM group with a tendency to statistical significance. The median IGF-1 was lower in diabetes (92.7 vs. 114.1 ng/ml, p=0.014) and positively correlated with muscle strength (r=0.472, p < 0.001). The sarcopenia index negatively correlated with muscle strength (r=-0.402, p=0.021) and positively with HbA 1c (r=0.514, p=0.035). Severe sarcopenia (according to EWGSOP2) was diagnosed in only one patient with T1DM, whose myostatin level did not differ from the range of patients without sarcopenia. CONCLUSION . Thus, patients with type 1 diabetes have higher myostatin levels, which correlates with with the level of HbA 1c . Low functional capacity in patients with type 1 diabetes is associated with HbA 1c levels, but is not directly related to myostatin levels.
- 26 July 2026
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 29 (3) , 245-255
Open AccessSarcopenia in postmenopausal patients with type 1 diabetes mellitus: characteristics of functional, laboratory, and instrumental indicators
BACKGROUND . Patients with type 1 diabetes mellitus (T1DM) are prone to earlier development of sarcopenia due to insulin deficiency, hyperglycemia, oxidative stress, and mitochondrial dysfunction. A pressing challenge in the management of these patients is the search for standardized diagnostic tools for the timely detection and monitoring of sarcopenia. OBJECTIVE . Comparative assessment of laboratory serum myokine levels in relation to muscle mass, strength, and function in postmenopausal women with type 1 diabetes and controls without diabetes. MATERIALS AND METHODS . A single-center, cross-sectional comparative study was conducted in women with type 1 diabetes (n=40) and a control group (n=40) aged 50–75 years. The SARC-F questionnaire, laboratory parameters (myostatin, follistatin, cystatin C, lipocalin 2, IGF-1), muscle mass (iDXA densitometry), strength (wrist dynamometry), and function (short-form exercise battery) were assessed. Statistical processing was performed in Statistica 14.0.0.15, IBM SPSS Statistics 23 using the Mann-Whitney, Fisher, and Spearman correlation tests. RESULTS . The age of the patients was 60 [56;64] years in the T1DM group and 64 [60;66] years in the control group (p=0.029). Glycated hemoglobin (HbA 1c ) in the T1DM group was 8.0% [7.6;9.3] with a diabetes duration of 26 [13;42] years. The myostatin level was significantly higher in T1DM 52.73 [46.45;58.26] mg/ml versus 21.46 [19.07;24.74] in the control (p < 0.001) and positively correlated with HbA 1c (r=0.544, p < 0.001), but not with muscle strength and mass. HbA1c negatively correlated with the time it took to get up from a chair 5 times. No differences were found in the levels of follistatin, lipocalin 2, cystatin C. Wrist dynamometry strength and walking speed were lower in the T1DM group with a tendency to statistical significance. The median IGF-1 was lower in diabetes (92.7 vs. 114.1 ng/ml, p=0.014) and positively correlated with muscle strength (r=0.472, p < 0.001). The sarcopenia index negatively correlated with muscle strength (r=-0.402, p=0.021) and positively with HbA 1c (r=0.514, p=0.035). Severe sarcopenia (according to EWGSOP2) was diagnosed in only one patient with T1DM, whose myostatin level did not differ from the range of patients without sarcopenia. CONCLUSION . Thus, patients with type 1 diabetes have higher myostatin levels, which correlates with with the level of HbA 1c . Low functional capacity in patients with type 1 diabetes is associated with HbA 1c levels, but is not directly related to myostatin levels.
- 18 May 2026
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 29 (2) , 104-136
Clinical and Epidemiological Analysis of Diabetes Mellitus Indicators in the Russian Federation, updated January 1, 2026
BACKGROUND . The system for clinical and epidemiological monitoring of diabetes mellitus (DM) in the Russian Federation (RF) was established by Endocrinology Research Centre in 1996 as part of the Federal Program "Diabetes Mellitus." The DM database (previously the registry) has become a key tool for analyzing the most important indicators of patients with DM, necessary for assessing the clinical status and the effectiveness of therapeutic strategies to improve the quality of care and make management decisions in healthcare. AIMS. To analyze epidemiological and clinical-therapeutic DM indicators: prevalence, incidence, age of onset, carbohydrate metabolism control and the proportion of obese patients, changes in the structure of hypoglycemic therapy (HLT), the prevalence of diabetic complications in the Russian population of DM patients in the RF. MATERIALS AND METHODS . Research object: "Database of Clinical and Epidemiological Monitoring of Diabetes Mellitus in the Russian Federation," including patients with diabetes mellitus from 89 regions of the Russian Federation (Registration Certificate No. 2020622447, http://diaregistry.ru), copyright holder: Endocrinology Research Centre. Data extraction date: January 1, 2026. The data are presented as of 01.01.2026 and in dynamics. RESULTS . The total number of DM patients in the RF as of 01.01.2026 was 5,814,928 (3.9% of the Russian population), of which 308,605 (5.3%) had type 1 diabetes (T1DM), 5,366,995 (92.3%) had type 2 diabetes (T2DM), and 139,328 (2.4%) had other types of diabetes. Over 30 years of clinical and epidemiological monitoring in the period 1996–2025, the prevalence increased as follows: T1DM by 3.3 times from 62.0 to 205.7/100 thousand population, T2DM by 8.6 times — from 416.6 to 3569.0/100 thousand population. The incidence increased in T1DM by 1.3 times from 6.3 to 8.1/100 thousand population; in T2DM by 4 times from 55.9 to 259.8/100 thousand population. Among the causes of death, cardiovascular (CV) pathology (heart attack, stroke, heart failure, acute CV disorders) ranks first, accounting for 36.9% T1DM and 51.1% of T2DM. Life time with diabetes in the period 2010–2025 increased: T1DM 15.3→20.4 years, T2DM 10.2→11.8 years. The number of patients with the target HbA1c level CONCLUSIONS . The obtained data, based on long-term dynamic clinical and epidemiological monitoring of diabetes mellitus, demonstrate the effectiveness of systematization and control the most important characteristics of diabetes on a single platform, which allows for the implementation of disease management strategies in clinical practice by optimizing the patient management algorithms.
- 18 May 2026
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 29 (2) , 104-136
Clinical and Epidemiological Analysis of Diabetes Mellitus Indicators in the Russian Federation, updated January 1, 2026
BACKGROUND . The system for clinical and epidemiological monitoring of diabetes mellitus (DM) in the Russian Federation (RF) was established by Endocrinology Research Centre in 1996 as part of the Federal Program "Diabetes Mellitus." The DM database (previously the registry) has become a key tool for analyzing the most important indicators of patients with DM, necessary for assessing the clinical status and the effectiveness of therapeutic strategies to improve the quality of care and make management decisions in healthcare. AIMS. To analyze epidemiological and clinical-therapeutic DM indicators: prevalence, incidence, age of onset, carbohydrate metabolism control and the proportion of obese patients, changes in the structure of hypoglycemic therapy (HLT), the prevalence of diabetic complications in the Russian population of DM patients in the RF. MATERIALS AND METHODS . Research object: "Database of Clinical and Epidemiological Monitoring of Diabetes Mellitus in the Russian Federation," including patients with diabetes mellitus from 89 regions of the Russian Federation (Registration Certificate No. 2020622447, http://diaregistry.ru), copyright holder: Endocrinology Research Centre. Data extraction date: January 1, 2026. The data are presented as of 01.01.2026 and in dynamics. RESULTS . The total number of DM patients in the RF as of 01.01.2026 was 5,814,928 (3.9% of the Russian population), of which 308,605 (5.3%) had type 1 diabetes (T1DM), 5,366,995 (92.3%) had type 2 diabetes (T2DM), and 139,328 (2.4%) had other types of diabetes. Over 30 years of clinical and epidemiological monitoring in the period 1996–2025, the prevalence increased as follows: T1DM by 3.3 times from 62.0 to 205.7/100 thousand population, T2DM by 8.6 times — from 416.6 to 3569.0/100 thousand population. The incidence increased in T1DM by 1.3 times from 6.3 to 8.1/100 thousand population; in T2DM by 4 times from 55.9 to 259.8/100 thousand population. Among the causes of death, cardiovascular (CV) pathology (heart attack, stroke, heart failure, acute CV disorders) ranks first, accounting for 36.9% T1DM and 51.1% of T2DM. Life time with diabetes in the period 2010–2025 increased: T1DM 15.3→20.4 years, T2DM 10.2→11.8 years. The number of patients with the target HbA1c level CONCLUSIONS . The obtained data, based on long-term dynamic clinical and epidemiological monitoring of diabetes mellitus, demonstrate the effectiveness of systematization and control the most important characteristics of diabetes on a single platform, which allows for the implementation of disease management strategies in clinical practice by optimizing the patient management algorithms.
- Open Access
- 3 December 2025
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 28 (5) , 480-486
Repeat kidney transplantation in a patient with type 1 diabetes mellitus and chronic pyelonephritis: a clinical case
Cadaveric kidney allotransplantation remains the most effective and safest therapeutic option for end-stage renal disease in patients with diabetes mellitus. Successful graft survival requires consideration of multiple factors that may contribute to transplant injury. Particular emphasis should be placed on minimizing the risk of transplant-associated infectious complications arising in the context of immunosuppressive therapy. We report a clinical case of kidney graft rejection in a female patient, occurring shortly after an episode of acute pyelonephritis and subsequent repeat cadaveric kidney allotransplantation.
- 3 December 2025
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 28 (5) , 480-486
Open AccessRepeat kidney transplantation in a patient with type 1 diabetes mellitus and chronic pyelonephritis: a clinical case
Cadaveric kidney allotransplantation remains the most effective and safest therapeutic option for end-stage renal disease in patients with diabetes mellitus. Successful graft survival requires consideration of multiple factors that may contribute to transplant injury. Particular emphasis should be placed on minimizing the risk of transplant-associated infectious complications arising in the context of immunosuppressive therapy. We report a clinical case of kidney graft rejection in a female patient, occurring shortly after an episode of acute pyelonephritis and subsequent repeat cadaveric kidney allotransplantation.
- Open Access
- 11 August 2025
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (6) , 4466
Cardiovascular risk and chronic kidney disease: strategies for cardiac and renal protection. Interdisciplinary consensus
The consensus was developed by experts from the Russian Scientific Medical Society of Internal Medicine, the Russian Society for the Prevention of Noncommunicable Diseases, the National Nephrology Association, the Professional Nephrology Association, the Russian Society of Cardiology, the Russian Medical Society for Arterial Hypertension, the Heart Failure Society, the National Atherosclerosis Society, the Russian Endocrinology Association, and the Russian Gerontology and Geriatrics Association.The expert consensus opinion was compiled on the basis of the relevant sections of national and international clinical guidelines on chronic kidney disease, prevention and treatment of atherosclerosis, hypertension, diabetes and heart failure.
- 11 August 2025
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (6) , 4466
Open AccessCardiovascular risk and chronic kidney disease: strategies for cardiac and renal protection. Interdisciplinary consensus
The consensus was developed by experts from the Russian Scientific Medical Society of Internal Medicine, the Russian Society for the Prevention of Noncommunicable Diseases, the National Nephrology Association, the Professional Nephrology Association, the Russian Society of Cardiology, the Russian Medical Society for Arterial Hypertension, the Heart Failure Society, the National Atherosclerosis Society, the Russian Endocrinology Association, and the Russian Gerontology and Geriatrics Association.The expert consensus opinion was compiled on the basis of the relevant sections of national and international clinical guidelines on chronic kidney disease, prevention and treatment of atherosclerosis, hypertension, diabetes and heart failure.
- Open Access
- 23 May 2025
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 28 (2) , 243-251
Sodium-glucose cotransporter 2 inhibitors as potential anticancer agents
Oncological diseases are one of the leading causes of mortality in the world. Despite the intensive search for new methods to increase the efficacy and safety of antineoplastic therapy and to reduce resistance to it by malignant tumors, treatment issues still remain unresolved in clinical oncology. This review analyses experimental data on the antineoplastic effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors: the reasons why SGLT2 inhibitors can be used for the treatment of malignant tumors are presented, class-specificity and dose-dependence of the antineoplastic effect of the drugs are determined. Possible mechanisms of antitumor effect of glyflozins are described in detail, among which, in addition to reduction of glucose entry into tumor cells, inhibition of Wnt/β-catenin signalling pathway, enhancement of AMP activated protein kinase activity with subsequent change of lipid profile of tumor cells and inhibition of mTOR protein kinase (mammalian target of rapamycin), disruption of DNA and RNA synthesis in malignant tumor cells, etc. play a significant role. Considerable space is devoted to the pro-oncogenic effect of SGLT2 inhibitors, previously undisputed and now disproved, as well as to the interaction of this class of antidiabetic agents with other antitumor treatment in the context of efficacy, safety and therapeutic resistance.
- 23 May 2025
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 28 (2) , 243-251
Open AccessSodium-glucose cotransporter 2 inhibitors as potential anticancer agents
Oncological diseases are one of the leading causes of mortality in the world. Despite the intensive search for new methods to increase the efficacy and safety of antineoplastic therapy and to reduce resistance to it by malignant tumors, treatment issues still remain unresolved in clinical oncology. This review analyses experimental data on the antineoplastic effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors: the reasons why SGLT2 inhibitors can be used for the treatment of malignant tumors are presented, class-specificity and dose-dependence of the antineoplastic effect of the drugs are determined. Possible mechanisms of antitumor effect of glyflozins are described in detail, among which, in addition to reduction of glucose entry into tumor cells, inhibition of Wnt/β-catenin signalling pathway, enhancement of AMP activated protein kinase activity with subsequent change of lipid profile of tumor cells and inhibition of mTOR protein kinase (mammalian target of rapamycin), disruption of DNA and RNA synthesis in malignant tumor cells, etc. play a significant role. Considerable space is devoted to the pro-oncogenic effect of SGLT2 inhibitors, previously undisputed and now disproved, as well as to the interaction of this class of antidiabetic agents with other antitumor treatment in the context of efficacy, safety and therapeutic resistance.
- Open Access
- 23 May 2025
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 28 (2) , 151-163
Markers of inflammation, fibrosis, endothelial dysfunction, and podocytopathy in patients with long-term type 1 diabetes mellitus
BACKGROUND: A comprehensive assessment of biomarkers involved in the development of systemic inflammation in patients with long-term type 1 diabetes mellitus (T1D), accompanied by the development and progression of cardiac and renal pathology, may allow stratification of patients according to specific inflammatory activity and help in the search for new therapeutic prevention and treatment options.AIM: To evaluate markers of inflammation, fibrosis, endothelial dysfunction, and podocytopathy in patients with prolonged course of T1D (≥ 20 years).MATERIALS AND METHODS: The study consisted of 2 stages. In the first stage, a single-center, cross-sectional study of 133 patients was conducted. Of these, 87 patients with 10-year data available were included in the second stage of the study with dynamic assessment of parameters. All patients were examined and treated at the Endocrinology Research Centre of the Ministry of Health of Russia from 2011 to 2024. Patients were divided into several groups: without chronic kidney disease (CKD) and with CKD at different stages. In addition to standard laboratory parameters, the levels of matrix metalloproteinase-9 (MMP-9), brain natriuretic hormone (NT-proBNP), transforming growth factor beta-1 (TGF-β1), asymmetric dimethylarginine (ADMA), monocyte chemotactic factor-1 (MCP-1), osteopontin, and tumor necrosis factor receptors type 1 (TNFRSF1A) and type 2 (TNFRSF1B), cystatin C in blood, nephrin, podocin in urine were studied using commercial kits in accordance with manufacturers’ recommendations. Based on the values of the regression coefficients, the estimated glomerular filtration rate (eGFR) showed an inverse relationship with the development of chronic heart failure (CHF), while podocin exhibited a positive relationship with acute kidney injury (AKI). The risk of CHF decreased with every 1 mL/min/1.73 m² increase in eGFR, OR=1.12 (95% CI: 1.02–1.22, P=0.015). The risk of AKI increased with every 1 ng/mL increase in podocin level, OR = 1.43 (95% CI: 1.01–2.03, P=0.047).RESULTS: According to the criteria of CKD, preserved kidney function was observed in 43.2% of patients (n=54), the rest were at various stages of CKD. The prevalence of late complications of diabetes among the examined patients was high and increased as renal dysfunction progressed. Individuals with CKD showed increased levels of ADMA (PCONCLUSION: In individuals with a long history of T1D, a significant role of factors of endothelial dysfunction, inflammation and fibrosis, podocytopathy in the development and progression of CKD with involvement of the cardiovascular system in the pathological process has been determined.
- 23 May 2025
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 28 (2) , 151-163
Open AccessMarkers of inflammation, fibrosis, endothelial dysfunction, and podocytopathy in patients with long-term type 1 diabetes mellitus
BACKGROUND: A comprehensive assessment of biomarkers involved in the development of systemic inflammation in patients with long-term type 1 diabetes mellitus (T1D), accompanied by the development and progression of cardiac and renal pathology, may allow stratification of patients according to specific inflammatory activity and help in the search for new therapeutic prevention and treatment options.AIM: To evaluate markers of inflammation, fibrosis, endothelial dysfunction, and podocytopathy in patients with prolonged course of T1D (≥ 20 years).MATERIALS AND METHODS: The study consisted of 2 stages. In the first stage, a single-center, cross-sectional study of 133 patients was conducted. Of these, 87 patients with 10-year data available were included in the second stage of the study with dynamic assessment of parameters. All patients were examined and treated at the Endocrinology Research Centre of the Ministry of Health of Russia from 2011 to 2024. Patients were divided into several groups: without chronic kidney disease (CKD) and with CKD at different stages. In addition to standard laboratory parameters, the levels of matrix metalloproteinase-9 (MMP-9), brain natriuretic hormone (NT-proBNP), transforming growth factor beta-1 (TGF-β1), asymmetric dimethylarginine (ADMA), monocyte chemotactic factor-1 (MCP-1), osteopontin, and tumor necrosis factor receptors type 1 (TNFRSF1A) and type 2 (TNFRSF1B), cystatin C in blood, nephrin, podocin in urine were studied using commercial kits in accordance with manufacturers’ recommendations. Based on the values of the regression coefficients, the estimated glomerular filtration rate (eGFR) showed an inverse relationship with the development of chronic heart failure (CHF), while podocin exhibited a positive relationship with acute kidney injury (AKI). The risk of CHF decreased with every 1 mL/min/1.73 m² increase in eGFR, OR=1.12 (95% CI: 1.02–1.22, P=0.015). The risk of AKI increased with every 1 ng/mL increase in podocin level, OR = 1.43 (95% CI: 1.01–2.03, P=0.047).RESULTS: According to the criteria of CKD, preserved kidney function was observed in 43.2% of patients (n=54), the rest were at various stages of CKD. The prevalence of late complications of diabetes among the examined patients was high and increased as renal dysfunction progressed. Individuals with CKD showed increased levels of ADMA (PCONCLUSION: In individuals with a long history of T1D, a significant role of factors of endothelial dysfunction, inflammation and fibrosis, podocytopathy in the development and progression of CKD with involvement of the cardiovascular system in the pathological process has been determined.